Maverick of Marketing: How B2B Marketers Can Validate Asking for More Budget

 

With the 2022 budget season heating up, Shannon Maverick, host of Maverick of Marketing, talked to an expert in marketing about his take on how marketers can validate asking for more budget. Scott Todaro, the CMO at Plannuh, Inc. Todaro brought his near thirty years of experience along with him on this journey to navigate the uncertain jungle of marketing budgets.

 Todaro saw a discrepancy between the tools marketers use today to validate their programs’ effectiveness and the language CFOs understand. And with CFOs dangling the purse strings, a marketing team must show the true ROI and value of their activities.

“What you need to do is be able to say is, ‘I spent this much, and we got this much value back,’” Todaro said. “And when you can say that, then they will give you money.”

 Todaro noted that the game is not the same as when he came out of business school in 1992. Then, 27 percent of all CEOs had a marketing background. Today the number is down to three percent.

 “And here’s what’s happened,” Todaro said. “Heads of marketing knew the product, knew the audience better than anyone. They did focus groups. They did surveys. They really did the research to understand the buyer.” Today, It’s a different story.

 “In B2B, a lot of times now the head of marketing’s responsible for lead generation to support the sales team,” Todaro said. “The sales team’s now taken over things like pricing and packaging, or the product team has taken over pricing and packaging.”

Be sure to get your complimentary copy of the ‘The Next CMO’.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More